Abstract
Quantitative methods for testing fibrinolytic agents in vivo are described. Methods based on the incorporation into the clot of P 32 labeled blood cells or Cr 51 labeled erythrocytes were found to be unsatisfactory. Clots were produced with I 131 labeled fibrinogen. Dissolution of a clot resulted in decrease of radioactivity. This was recorded by placing segments of blood vessels in a special lead shield containing a scintillation detector head, connected to a radiation rate meter and an Esterline recorder. Pulmonary, peripheral and coronary emboli were produced by injecting radioactive clots produced and ground, in vitro. Using these methods it was found that maximal tolerated doses of trypsin showed no significant fibrinolytic effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
